+关注
CHOONHIANG
暂无个人介绍
IP属地：未知
5
关注
0
粉丝
0
主题
0
勋章
主贴
热门
CHOONHIANG
2021-11-09
Good
Magic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote>
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3582018039011325","uuid":"3582018039011325","gmtCreate":1618924198091,"gmtModify":1618924198091,"name":"CHOONHIANG","pinyin":"choonhiang","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":5,"tweetSize":1,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.17","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":844754005,"gmtCreate":1636463946415,"gmtModify":1636463946480,"author":{"id":"3582018039011325","authorId":"3582018039011325","name":"CHOONHIANG","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582018039011325","idStr":"3582018039011325"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844754005","repostId":"1176992919","repostType":4,"repost":{"id":"1176992919","kind":"news","pubTimestamp":1636462320,"share":"https://www.laohu8.com/m/news/1176992919?lang=zh_CN&edition=full","pubTime":"2021-11-09 20:52","market":"us","language":"en","title":"Magic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176992919","media":"Bloomberg","summary":"(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic m","content":"<p>(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.</p><p><blockquote>（彭博社）——Compass Pathways Plc基于裸盖菇素（即所谓的神奇蘑菇）的实验性疗法在一项中期临床试验中显示出希望，该试验针对的是抑郁症通过其他治疗没有改善的患者。</blockquote></p><p> Nearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.</p><p><blockquote>根据精神病学家使用的量表测量，接受最高剂量Compass Pathways候选药物COMP360治疗的近四分之一的人在三个月后抑郁症的严重程度有所减轻。COMP360是迷幻蘑菇中活性成分的专利配方。</blockquote></p><p> “A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.</p><p><blockquote>Compass首席执行官乔治·戈德史密斯(George Goldsmith)在结果在新闻稿中公布之前接受采访时表示：“高剂量的裸盖菇素在第二天对很多人立即起作用，并且继续起作用。”除了药物之外，试验中的患者还接受了心理咨询。</blockquote></p><p> Goldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.</p><p><blockquote>戈德史密斯表示，该公司相信其233人的2b期研究是有史以来对裸盖菇素进行的规模最大、最严格的测试。他称这项对照双盲试验意义重大，因为它涉及10个国家和7种语言。只有那些之前尝试过两种或两种以上抑郁症药物但未能缓解的人被包括在内。</blockquote></p><p> The results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.</p><p><blockquote>新兴迷幻药行业的投资者，特别是这家英国公司的最大股东Atai Life Sciences NV将对结果感兴趣。今年到目前为止，迷幻股的道路并不平坦。</blockquote></p><p> Compass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.</p><p><blockquote>周二盘前交易中，Compass股价上涨42%。截至纽约上午7点23分，该股上涨15%，至49.65美元，Atai上涨7.8%，至18美元。</blockquote></p><p> Many startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.</p><p><blockquote>该领域的许多初创公司都围绕治疗中心或其他疗法建立了商业模式，宣扬裸盖菇素或类似分子的前景。虽然蘑菇已经被使用了几个世纪，但关于它们的临床数据很少。</blockquote></p><p> At the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.</p><p><blockquote>周一在迈阿密举行的迷幻药行业仙境会议上，一个小组的一些参与者谈到了Compass的结果可能产生连锁反应。</blockquote></p><p> “If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.</p><p><blockquote>H.C.生物技术分析师Patrick Trucchio表示：“如果Compass的数据是积极的，那么肯定不会出现资金紧缩。”温赖特公司，在试验结果公布之前。</blockquote></p><p> Goldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.</p><p><blockquote>戈德史密斯拒绝评论其结果是否可以外推到迷幻蘑菇中发现的天然裸盖菇素，称这些蘑菇含有其他化合物，并且没有COMP360的精确剂量和纯度，COMP360涉及胶囊中的一种晶体形式。</blockquote></p><p> Final Approval</p><p><blockquote>最终批准</blockquote></p><p> The company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.</p><p><blockquote>该公司需要进行更大规模的研究才能寻求最终监管机构的批准。戈德史密斯说，如果美国。美国食品和药物管理局对此表示同意，Compass可能会在2024年或2025年之前寻求最终批准。</blockquote></p><p> The medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.</p><p><blockquote>该药物已经获得该机构的“突破性疗法”称号，这意味着加快药物开发进程。Compass估计，全球有超过1亿人患有难治性抑郁症，多达30%的人试图自杀。</blockquote></p><p> There were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.</p><p><blockquote>最高剂量组有5名患者退出试验，而较低剂量组退出试验的人数约为两倍。大多数患者报告了至少一种主要为轻度或中度的副作用，包括头痛、恶心、疲劳和失眠。</blockquote></p><p> There were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.</p><p><blockquote>研究中还有12人表现出自杀行为或想法，或表现出伤害自己的意图。戈德史密斯说，这表明了在裸盖菇素治疗的同时进行治疗的重要性。该试验包括帮助患者处理其经历的“整合”会议，以及后续会议。</blockquote></p><p> Goldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.</p><p><blockquote>戈德史密斯说，一些问题行为发生在那些实际上没有对COMP360做出回应的人身上。在三名表现出自杀行为的参与者中，两名最初对治疗没有反应，而有自杀想法的患者都没有反应。他说，这可能是他们潜在疾病的影响，甚至是药物未能帮助他们的事实，而不是药物本身。</blockquote></p><p> “This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”</p><p><blockquote>“这不是灵丹妙药，”他说。“人们有如此高的期望。对一些人来说，这可能是他们认为可以尝试的最后一件事。”</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Magic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMagic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-09 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.</p><p><blockquote>（彭博社）——Compass Pathways Plc基于裸盖菇素（即所谓的神奇蘑菇）的实验性疗法在一项中期临床试验中显示出希望，该试验针对的是抑郁症通过其他治疗没有改善的患者。</blockquote></p><p> Nearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.</p><p><blockquote>根据精神病学家使用的量表测量，接受最高剂量Compass Pathways候选药物COMP360治疗的近四分之一的人在三个月后抑郁症的严重程度有所减轻。COMP360是迷幻蘑菇中活性成分的专利配方。</blockquote></p><p> “A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.</p><p><blockquote>Compass首席执行官乔治·戈德史密斯(George Goldsmith)在结果在新闻稿中公布之前接受采访时表示：“高剂量的裸盖菇素在第二天对很多人立即起作用，并且继续起作用。”除了药物之外，试验中的患者还接受了心理咨询。</blockquote></p><p> Goldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.</p><p><blockquote>戈德史密斯表示，该公司相信其233人的2b期研究是有史以来对裸盖菇素进行的规模最大、最严格的测试。他称这项对照双盲试验意义重大，因为它涉及10个国家和7种语言。只有那些之前尝试过两种或两种以上抑郁症药物但未能缓解的人被包括在内。</blockquote></p><p> The results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.</p><p><blockquote>新兴迷幻药行业的投资者，特别是这家英国公司的最大股东Atai Life Sciences NV将对结果感兴趣。今年到目前为止，迷幻股的道路并不平坦。</blockquote></p><p> Compass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.</p><p><blockquote>周二盘前交易中，Compass股价上涨42%。截至纽约上午7点23分，该股上涨15%，至49.65美元，Atai上涨7.8%，至18美元。</blockquote></p><p> Many startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.</p><p><blockquote>该领域的许多初创公司都围绕治疗中心或其他疗法建立了商业模式，宣扬裸盖菇素或类似分子的前景。虽然蘑菇已经被使用了几个世纪，但关于它们的临床数据很少。</blockquote></p><p> At the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.</p><p><blockquote>周一在迈阿密举行的迷幻药行业仙境会议上，一个小组的一些参与者谈到了Compass的结果可能产生连锁反应。</blockquote></p><p> “If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.</p><p><blockquote>H.C.生物技术分析师Patrick Trucchio表示：“如果Compass的数据是积极的，那么肯定不会出现资金紧缩。”温赖特公司，在试验结果公布之前。</blockquote></p><p> Goldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.</p><p><blockquote>戈德史密斯拒绝评论其结果是否可以外推到迷幻蘑菇中发现的天然裸盖菇素，称这些蘑菇含有其他化合物，并且没有COMP360的精确剂量和纯度，COMP360涉及胶囊中的一种晶体形式。</blockquote></p><p> Final Approval</p><p><blockquote>最终批准</blockquote></p><p> The company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.</p><p><blockquote>该公司需要进行更大规模的研究才能寻求最终监管机构的批准。戈德史密斯说，如果美国。美国食品和药物管理局对此表示同意，Compass可能会在2024年或2025年之前寻求最终批准。</blockquote></p><p> The medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.</p><p><blockquote>该药物已经获得该机构的“突破性疗法”称号，这意味着加快药物开发进程。Compass估计，全球有超过1亿人患有难治性抑郁症，多达30%的人试图自杀。</blockquote></p><p> There were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.</p><p><blockquote>最高剂量组有5名患者退出试验，而较低剂量组退出试验的人数约为两倍。大多数患者报告了至少一种主要为轻度或中度的副作用，包括头痛、恶心、疲劳和失眠。</blockquote></p><p> There were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.</p><p><blockquote>研究中还有12人表现出自杀行为或想法，或表现出伤害自己的意图。戈德史密斯说，这表明了在裸盖菇素治疗的同时进行治疗的重要性。该试验包括帮助患者处理其经历的“整合”会议，以及后续会议。</blockquote></p><p> Goldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.</p><p><blockquote>戈德史密斯说，一些问题行为发生在那些实际上没有对COMP360做出回应的人身上。在三名表现出自杀行为的参与者中，两名最初对治疗没有反应，而有自杀想法的患者都没有反应。他说，这可能是他们潜在疾病的影响，甚至是药物未能帮助他们的事实，而不是药物本身。</blockquote></p><p> “This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”</p><p><blockquote>“这不是灵丹妙药，”他说。“人们有如此高的期望。对一些人来说，这可能是他们认为可以尝试的最后一件事。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/magic-mushroom-based-therapy-depression-122402488.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMPS":"COMPASS Pathways plc"},"source_url":"https://finance.yahoo.com/news/magic-mushroom-based-therapy-depression-122402488.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176992919","content_text":"(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.\nNearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.\n“A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.\nGoldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.\nThe results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.\nCompass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.\nMany startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.\nAt the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.\n“If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.\nGoldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.\nFinal Approval\nThe company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.\nThe medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.\nThere were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.\nThere were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.\nGoldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.\n“This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”","news_type":1,"symbols_score_info":{"CMPS":0.9}},"isVote":1,"tweetType":1,"viewCount":1926,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":844754005,"gmtCreate":1636463946415,"gmtModify":1636463946480,"author":{"id":"3582018039011325","authorId":"3582018039011325","name":"CHOONHIANG","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3582018039011325","idStr":"3582018039011325"},"themes":[],"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/844754005","repostId":"1176992919","repostType":4,"repost":{"id":"1176992919","kind":"news","pubTimestamp":1636462320,"share":"https://www.laohu8.com/m/news/1176992919?lang=zh_CN&edition=full","pubTime":"2021-11-09 20:52","market":"us","language":"en","title":"Magic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176992919","media":"Bloomberg","summary":"(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic m","content":"<p>(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.</p><p><blockquote>（彭博社）——Compass Pathways Plc基于裸盖菇素（即所谓的神奇蘑菇）的实验性疗法在一项中期临床试验中显示出希望，该试验针对的是抑郁症通过其他治疗没有改善的患者。</blockquote></p><p> Nearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.</p><p><blockquote>根据精神病学家使用的量表测量，接受最高剂量Compass Pathways候选药物COMP360治疗的近四分之一的人在三个月后抑郁症的严重程度有所减轻。COMP360是迷幻蘑菇中活性成分的专利配方。</blockquote></p><p> “A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.</p><p><blockquote>Compass首席执行官乔治·戈德史密斯(George Goldsmith)在结果在新闻稿中公布之前接受采访时表示：“高剂量的裸盖菇素在第二天对很多人立即起作用，并且继续起作用。”除了药物之外，试验中的患者还接受了心理咨询。</blockquote></p><p> Goldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.</p><p><blockquote>戈德史密斯表示，该公司相信其233人的2b期研究是有史以来对裸盖菇素进行的规模最大、最严格的测试。他称这项对照双盲试验意义重大，因为它涉及10个国家和7种语言。只有那些之前尝试过两种或两种以上抑郁症药物但未能缓解的人被包括在内。</blockquote></p><p> The results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.</p><p><blockquote>新兴迷幻药行业的投资者，特别是这家英国公司的最大股东Atai Life Sciences NV将对结果感兴趣。今年到目前为止，迷幻股的道路并不平坦。</blockquote></p><p> Compass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.</p><p><blockquote>周二盘前交易中，Compass股价上涨42%。截至纽约上午7点23分，该股上涨15%，至49.65美元，Atai上涨7.8%，至18美元。</blockquote></p><p> Many startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.</p><p><blockquote>该领域的许多初创公司都围绕治疗中心或其他疗法建立了商业模式，宣扬裸盖菇素或类似分子的前景。虽然蘑菇已经被使用了几个世纪，但关于它们的临床数据很少。</blockquote></p><p> At the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.</p><p><blockquote>周一在迈阿密举行的迷幻药行业仙境会议上，一个小组的一些参与者谈到了Compass的结果可能产生连锁反应。</blockquote></p><p> “If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.</p><p><blockquote>H.C.生物技术分析师Patrick Trucchio表示：“如果Compass的数据是积极的，那么肯定不会出现资金紧缩。”温赖特公司，在试验结果公布之前。</blockquote></p><p> Goldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.</p><p><blockquote>戈德史密斯拒绝评论其结果是否可以外推到迷幻蘑菇中发现的天然裸盖菇素，称这些蘑菇含有其他化合物，并且没有COMP360的精确剂量和纯度，COMP360涉及胶囊中的一种晶体形式。</blockquote></p><p> Final Approval</p><p><blockquote>最终批准</blockquote></p><p> The company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.</p><p><blockquote>该公司需要进行更大规模的研究才能寻求最终监管机构的批准。戈德史密斯说，如果美国。美国食品和药物管理局对此表示同意，Compass可能会在2024年或2025年之前寻求最终批准。</blockquote></p><p> The medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.</p><p><blockquote>该药物已经获得该机构的“突破性疗法”称号，这意味着加快药物开发进程。Compass估计，全球有超过1亿人患有难治性抑郁症，多达30%的人试图自杀。</blockquote></p><p> There were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.</p><p><blockquote>最高剂量组有5名患者退出试验，而较低剂量组退出试验的人数约为两倍。大多数患者报告了至少一种主要为轻度或中度的副作用，包括头痛、恶心、疲劳和失眠。</blockquote></p><p> There were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.</p><p><blockquote>研究中还有12人表现出自杀行为或想法，或表现出伤害自己的意图。戈德史密斯说，这表明了在裸盖菇素治疗的同时进行治疗的重要性。该试验包括帮助患者处理其经历的“整合”会议，以及后续会议。</blockquote></p><p> Goldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.</p><p><blockquote>戈德史密斯说，一些问题行为发生在那些实际上没有对COMP360做出回应的人身上。在三名表现出自杀行为的参与者中，两名最初对治疗没有反应，而有自杀想法的患者都没有反应。他说，这可能是他们潜在疾病的影响，甚至是药物未能帮助他们的事实，而不是药物本身。</blockquote></p><p> “This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”</p><p><blockquote>“这不是灵丹妙药，”他说。“人们有如此高的期望。对一些人来说，这可能是他们认为可以尝试的最后一件事。”</blockquote></p><p></p>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Magic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMagic Mushroom-Based Therapy for Depression Shows Promise<blockquote>基于神奇蘑菇的抑郁症疗法显示出希望</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Bloomberg</strong><span class=\"h-time small\">2021-11-09 20:52</span>\n</p>\n</h4>\n</header>\n<article>\n<p>(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.</p><p><blockquote>（彭博社）——Compass Pathways Plc基于裸盖菇素（即所谓的神奇蘑菇）的实验性疗法在一项中期临床试验中显示出希望，该试验针对的是抑郁症通过其他治疗没有改善的患者。</blockquote></p><p> Nearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.</p><p><blockquote>根据精神病学家使用的量表测量，接受最高剂量Compass Pathways候选药物COMP360治疗的近四分之一的人在三个月后抑郁症的严重程度有所减轻。COMP360是迷幻蘑菇中活性成分的专利配方。</blockquote></p><p> “A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.</p><p><blockquote>Compass首席执行官乔治·戈德史密斯(George Goldsmith)在结果在新闻稿中公布之前接受采访时表示：“高剂量的裸盖菇素在第二天对很多人立即起作用，并且继续起作用。”除了药物之外，试验中的患者还接受了心理咨询。</blockquote></p><p> Goldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.</p><p><blockquote>戈德史密斯表示，该公司相信其233人的2b期研究是有史以来对裸盖菇素进行的规模最大、最严格的测试。他称这项对照双盲试验意义重大，因为它涉及10个国家和7种语言。只有那些之前尝试过两种或两种以上抑郁症药物但未能缓解的人被包括在内。</blockquote></p><p> The results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.</p><p><blockquote>新兴迷幻药行业的投资者，特别是这家英国公司的最大股东Atai Life Sciences NV将对结果感兴趣。今年到目前为止，迷幻股的道路并不平坦。</blockquote></p><p> Compass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.</p><p><blockquote>周二盘前交易中，Compass股价上涨42%。截至纽约上午7点23分，该股上涨15%，至49.65美元，Atai上涨7.8%，至18美元。</blockquote></p><p> Many startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.</p><p><blockquote>该领域的许多初创公司都围绕治疗中心或其他疗法建立了商业模式，宣扬裸盖菇素或类似分子的前景。虽然蘑菇已经被使用了几个世纪，但关于它们的临床数据很少。</blockquote></p><p> At the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.</p><p><blockquote>周一在迈阿密举行的迷幻药行业仙境会议上，一个小组的一些参与者谈到了Compass的结果可能产生连锁反应。</blockquote></p><p> “If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.</p><p><blockquote>H.C.生物技术分析师Patrick Trucchio表示：“如果Compass的数据是积极的，那么肯定不会出现资金紧缩。”温赖特公司，在试验结果公布之前。</blockquote></p><p> Goldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.</p><p><blockquote>戈德史密斯拒绝评论其结果是否可以外推到迷幻蘑菇中发现的天然裸盖菇素，称这些蘑菇含有其他化合物，并且没有COMP360的精确剂量和纯度，COMP360涉及胶囊中的一种晶体形式。</blockquote></p><p> Final Approval</p><p><blockquote>最终批准</blockquote></p><p> The company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.</p><p><blockquote>该公司需要进行更大规模的研究才能寻求最终监管机构的批准。戈德史密斯说，如果美国。美国食品和药物管理局对此表示同意，Compass可能会在2024年或2025年之前寻求最终批准。</blockquote></p><p> The medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.</p><p><blockquote>该药物已经获得该机构的“突破性疗法”称号，这意味着加快药物开发进程。Compass估计，全球有超过1亿人患有难治性抑郁症，多达30%的人试图自杀。</blockquote></p><p> There were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.</p><p><blockquote>最高剂量组有5名患者退出试验，而较低剂量组退出试验的人数约为两倍。大多数患者报告了至少一种主要为轻度或中度的副作用，包括头痛、恶心、疲劳和失眠。</blockquote></p><p> There were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.</p><p><blockquote>研究中还有12人表现出自杀行为或想法，或表现出伤害自己的意图。戈德史密斯说，这表明了在裸盖菇素治疗的同时进行治疗的重要性。该试验包括帮助患者处理其经历的“整合”会议，以及后续会议。</blockquote></p><p> Goldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.</p><p><blockquote>戈德史密斯说，一些问题行为发生在那些实际上没有对COMP360做出回应的人身上。在三名表现出自杀行为的参与者中，两名最初对治疗没有反应，而有自杀想法的患者都没有反应。他说，这可能是他们潜在疾病的影响，甚至是药物未能帮助他们的事实，而不是药物本身。</blockquote></p><p> “This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”</p><p><blockquote>“这不是灵丹妙药，”他说。“人们有如此高的期望。对一些人来说，这可能是他们认为可以尝试的最后一件事。”</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.yahoo.com/news/magic-mushroom-based-therapy-depression-122402488.html\">Bloomberg</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CMPS":"COMPASS Pathways plc"},"source_url":"https://finance.yahoo.com/news/magic-mushroom-based-therapy-depression-122402488.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176992919","content_text":"(Bloomberg) -- Compass Pathways Plc’s experimental therapy based on psilocybin, or so-called magic mushrooms, showed promise in a midstage clinical trial in patients whose depression didn’t improve from other treatments.\nNearly a quarter of the people treated with the highest dose of Compass Pathways’ drug candidate, called COMP360, saw the severity of their depression reduced after three months, as measured on a scale used by psychiatrists. COMP360 is a patented formulation of the active ingredient in psychedelic mushrooms.\n“A high dose of psilocybin works immediately, the day after, for a large number of people, and continues to work,” Compass Chief Executive Officer George Goldsmith said in an interview before the results were made public in a press release. Patients in the trial also all received psychological counseling in addition to the drug.\nGoldsmith said the company believes its 233-person test, a Phase 2b study, is the largest and most rigorous ever done on psilocybin. He called the controlled, double-blind trial significant given it involved 10 countries and seven languages. Only people who had tried two or more prior medications for depression and failed to find relief were included.\nThe results will be of interest to investors in the nascent psychedelics industry, and in particular the U.K.-based company’s top shareholder, Atai Life Sciences NV. Psychedelic stocks have had a rocky road so far this year.\nCompass shares rose as much as 42% in volatile premarket trading Tuesday. They were up 15% to $49.65 at 7:23 a.m. in New York, while Atai advanced 7.8% to $18.\nMany startups in the space have business models built around treatment centers or other therapies that tout the promise of psilocybin or similar molecules. While mushrooms have been used for centuries, there are few clinical data on them.\nAt the Wonderland conference on the psychedelics industry in Miami on Monday, some participants on a panel addressed the potential for Compass’s results to have a ripple effect.\n“If the data is positive from Compass, there will definitely not be a funding crunch,” said Patrick Trucchio, a biotech analyst at H.C. Wainwright & Co., before the release of the trial results.\nGoldsmith declined to comment on whether its results could be extrapolated to natural psilocybin found in psychedelic mushrooms, saying those contain other compounds and don’t have the precise dosing and purity of COMP360, which involves a crystal form in capsules.\nFinal Approval\nThe company needs an even larger study before it can seek final regulatory approval. Goldsmith said that study could begin next year if the U.S. Food and Drug Administration agrees, and Compass could seek final approval by 2024 or 2025.\nThe medicine has already received the agency’s “breakthrough therapy” designation, which is meant to speed up the drug-development process. Compass estimates that more than 100 million people worldwide have treatment-resistant depression, and as many as 30% attempt suicide.\nThere were five patient withdrawals from the trial at the highest dose, compared with about twice as many people on the lower doses who left the trial. Most patients reported at least one mostly mild or moderate side effect, including headache, nausea, fatigue and insomnia.\nThere were also 12 people in the study who exhibited suicidal behavior or thoughts, or who showed intent to harm themselves. This shows the importance of having therapy alongside psilocybin-based treatments, Goldsmith said. The trial included “integration” sessions to help patients process their experience, as well as follow-up sessions.\nGoldsmith said some of the troubled behavior was among the people who hadn’t actually responded to COMP360. Among three participants who exhibited suicidal behavior, two didn’t initially respond to the treatment, while none of the patients with suicidal thoughts had responded. It’s possible that it may have been an effect of their underlying condition -- or even the fact that the drug had failed to help them -- rather than the drug itself, he said.\n“This is not a panacea,” he said. “People have such high expectations. And for some, this might be the last thing they think they can try.”","news_type":1,"symbols_score_info":{"CMPS":0.9}},"isVote":1,"tweetType":1,"viewCount":1926,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
